« Back
Home /
Rabusertib

Rabusertib

Item no.	HY-14720-10mM
Manufacturer	MedChem Express
CASRN	911222-45-2
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Neuroscience Neural Epigenetics Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.98
Citations	[1]King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.\|[2]Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8(9):e76662.
Smiles	BrC(C=C1NC(NC2=NC=C(N=C2)C)=O)=C(C=C1OC[C@H]3OCCNC3)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY2603618,IC-83
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; Checkpoint Kinase (Chk)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	436.30
Product Description	Rabusertib (LY2603618) is a potent and selective inhibitor of Chk1 with an IC50 of 7 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage
Isoform	Chk1; Chk2
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14720-10mM-safety-datasheet.pdf